In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioPartners GmbH

Division of Bioton SA
www.biopartners.ch

Latest From BioPartners GmbH

Europe Backs Celgene’s Pomalidomide And Aegerion’s Lomitapide

Positive opinions from Europe's top drug assessment panel in May have included a long-acting "biobetter" lipegfilgrastim from Teva, a once-weekly HGH injection from Biopartners GmbH, and a smallpox vaccine developed by Bavarian Nordic with funding from the U.S. BioShield program.

BioPharmaceutical Europe

Biosimilars: A New Kind Of Innovation

The lesson from first-generation biosimilars is that these aren't just small-molecule style copies. They require significant clinical and commercial support to overcome prescriber skepticism. For those lining up to tap into the next-generation opportunity, biosimilars represent a new kind of innovation, where the novelty lies in a drug's value-focused pricing, quality, cost-effective production, and in peripherals such as support-services and means of delivery. Although biosimilar market dynamics will vary from molecule to molecule, this emphasis on price and value rather than scientific breakthrough exemplifies a new definition of innovation in the biopharma sector.

BioPharmaceutical Europe

Biosimilars: EMEA Wants Approvals

European regulators’ guidelines on biosimilars show that they are serious about quickly approving cheaper follow-on biologics. The hurdles may come thereafter.
BioPharmaceutical Legal Issues

FDA Hesitates on Biogenerics

A long-awaited Food and Drug Administration (FDA) workshop held in mid-September, highlighted just how far the agency is from establishing a regulatory path for generic copies of biologics. Although it yielded few surprises, the meeting provided a concentrated public forum for interested parties to present in-depth views of all sides of the issue--an unusual event in itself
BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Biopartners Holdings AG
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Bioton SA
  • Senior Management
  • Conrad Savoy, CEO
    Philippe Tremml, PhD, Head, Bus. Dev.
    Sandro Gabaglio , Head, Fin. & Admin.
    Cornelius Sobel, PhD, CSO
  • Contact Info
  • BioPartners GmbH
    Phone: (41) 766 20 80
    Baarermatte
    Baar, 6340
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register